受强制性开放获取政策约束的文章 - Raffaele Califano了解详情
无法在其他位置公开访问的文章：3 篇
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
R Califano, A Greystoke, R Lal, J Thompson, S Popat
Lung Cancer 111, 51-58, 2017
强制性开放获取政策： National Institute for Health Research, UK
Can EBUS-TBNA provide an accurate diagnosis in patients found to have enlarged or FDG-avid lymph nodes during surveillance of previously treated lung cancer?: A retrospective study
M Evison, PAJ Crosbie, R Califano, Y Summers, J Martin, PV Barber, ...
Journal of bronchology & interventional pulmonology 22 (2), 114-120, 2015
强制性开放获取政策： Cancer Research UK
Novel therapeutic strategies for recurrent SCLC
L Moliner, B Zhang, G Lamberti, A Ardizzoni, LA Byers, R Califano
Critical Reviews in Oncology/Hematology 186, 104017, 2023
强制性开放获取政策： Government of Italy, AIRC Foundation for Cancer Research in Italy
可在其他位置公开访问的文章：22 篇
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ...
Nature 545 (7655), 446-451, 2017
强制性开放获取政策： US National Institutes of Health, Versus Arthritis, UK, Cancer Research UK …
Allele-specific HLA loss and immune escape in lung cancer evolution
N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ...
Cell 171 (6), 1259-1271. e11, 2017
强制性开放获取政策： Versus Arthritis, UK, Cancer Research UK, UK Medical Research Council …
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ...
Annals of Oncology 27, v1-v27, 2016
强制性开放获取政策： National Institute for Health Research, UK
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...
Cancer cell 33 (4), 649-663. e4, 2018
强制性开放获取政策： Blood Cancer UK, Cancer Research UK, UK Medical Research Council, National …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
强制性开放获取政策： US National Institutes of Health
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors
FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ...
Immunity 46 (4), 577-586, 2017
强制性开放获取政策： Blood Cancer UK, Cancer Research UK, UK Engineering and Physical Sciences …
Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial
DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ...
Journal of Clinical Oncology 38 (31), 3592-3603, 2020
强制性开放获取政策： US National Institutes of Health, National Institute for Health Research, UK
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
DA Fennell, S Ewings, C Ottensmeier, R Califano, GG Hanna, K Hill, ...
The Lancet Oncology 22 (11), 1530-1540, 2021
强制性开放获取政策： Cancer Research UK, UK Medical Research Council
Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma
L Khoja, P Lorigan, C Zhou, M Lancashire, J Booth, J Cummings, ...
Journal of Investigative Dermatology 133 (6), 1582-1590, 2013
强制性开放获取政策： Cancer Research UK
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
E Felip, A Ardizzoni, T Ciuleanu, M Cobo, K Laktionov, M Szilasi, ...
European Journal of Cancer 127, 160-172, 2020
强制性开放获取政策： National Institute for Health Research, UK
Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK
R Califano, N Tariq, S Compton, DA Fitzgerald, CA Harwood, R Lal, ...
Drugs 75, 1335-1348, 2015
强制性开放获取政策： Cancer Research UK
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) young oncologists committee burnout survey
S Banerjee, R Califano, J Corral, E de Azambuja, L De Mattos-Arruda, ...
Annals of Oncology 28 (7), 1590-1596, 2017
强制性开放获取政策： US National Institutes of Health, National Institute for Health Research, UK
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy–results from the randomised phase II ETOP/IFCT 4-12 …
S Peters, JL Pujol, U Dafni, M Dómine, S Popat, M Reck, J Andrade, ...
Annals of Oncology 33 (1), 67-79, 2022
强制性开放获取政策： US National Institutes of Health, National Institute for Health Research, UK
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial
E Lim, D Waller, K Lau, J Steele, A Pope, C Ali, R Bilancia, M Keni, ...
The Lancet Respiratory Medicine 12 (6), 457-466, 2024
强制性开放获取政策： British Heart Foundation, Cancer Research UK, UK Medical Research Council …
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
R Califano, R Lal, C Lewanski, MC Nicolson, CH Ottensmeier, S Popat, ...
Future Oncology 14 (23), 2415-2431, 2018
强制性开放获取政策： Cancer Research UK
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
A Greystoke, N Steele, HT Arkenau, F Blackhall, N Md Haris, CR Lindsay, ...
British Journal of Cancer 117 (7), 938-946, 2017
强制性开放获取政策： Cancer Research UK
Management of NSCLC disease progression after first-line EGFR tyrosine kinase inhibitors: what are the issues and potential therapies?
R Califano, O Romanidou, G Mountzios, L Landi, F Cappuzzo, F Blackhall
Drugs 76, 831-840, 2016
强制性开放获取政策： Cancer Research UK
出版信息和资助信息由计算机程序自动确定